GeneCentric Announces Series C Financing to Advance Novel Liquid Biopsy Platform for Precision Oncology

Original from: business wire

GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing. The proceeds will be used to launch and commercialize GeneCentric’s GenomicsNext™, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample. This novel gene expression platform will accelerate the growth of GeneCentric’s pipeline of predictive response signatures for oncology therapeutics development.

The funding round was led by Hatteras Venture Partners, with current participation from existing investors IAG Capital Partners, Alexandria Venture Investments, and Labcorp. The financing is expected to provide a cash runway for GeneCentric through 2026.

“While we see many new liquid biopsy companies seeking funding, GeneCentric has the most compelling opportunity we have identified,” said Clay Thorp, General Partner, Hatteras Ventures Partners. “GenomicsNext has the potential to become the ‘decoder ring’ for translating a broad array of tissue-based biomarkers into liquid biopsy formats. This could transform how patients are identified and how disease and treatments are monitored.”

“With a single blood sample from a cancer patient, our GenomicsNext liquid biopsy platform can determine the gene expression of drug target genes, molecular subtypes, and predictive gene signatures, in addition to mutations and fusions,” said Mike Milburn, PhD, President and CEO of GeneCentric Therapeutics. “We believe our unique fragmentomics technology will become the best-in-class application for yielding greater insights and biomarker coverage from liquid biopsies to better aid diagnosis and treatment selection for patients. We are grateful for the enthusiasm and support of our investors and expect to make the GenomicsNext platform commercially available as a powerful research tool for biopharmaceutical companies in 2025.”

Source: GeneCentric Announces Series C Financing to Advance Novel Liquid Biopsy Platform for Precision Oncology